β-sitosterol | 170638-09-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: β-sitosterol
• 英文别名: (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-ethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 170638-09-2
• 化学式: C₂₈H₄₈O
• 分子量: 400.689
• InChiKey: ODRAJQYBNQNYRL-LYLGZYPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  β-sitosterol 在 铂 作用下， 生成 acetic acid-(27-nor-5α-stigmastanyl-(3β)-ester)
  参考文献：
  名称：

  Mitsui, Journal of the Agricultural Chemical Society of Japan, 1940, vol. 16, p. 145

  摘要：

  DOI：
• 作为产物：
  描述：

  acetic acid-(24-chloro-27-nor-stigmasten-(5)-yl-(3β)-ester) 在 丙醇 、 sodium 作用下， 生成 β-sitosterol
  参考文献：
  名称：

  Mitsui, Nippon Nogeikagaku Kaishi, 1940, vol. 16, p. 917,923

  摘要：

  DOI：

文献信息

• [EN] MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF<br/>[FR] ARNM CODANT DES POLYPEPTIDES DE MODULATION IMMUNITAIRE ET LEURS UTILISATIONS
  申请人：MODERNA TX INC

  公开号：WO2021076805A1

  公开（公告）日：2021-04-22

  The disclosure features lipid nanoparticle (LNP) compositions comprising immune modulating polypeptides and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune modulating polypeptides, e.g., interleukin 2 (IL- 2) and/or granulocyte macrophage colony stimulating factor (GM-CSF). The LNP compositions of the present disclosure can stimulate T regulatory cells, e.g., increase the level and/or activity of T regulatory cells in vivo or ex vivo.

  披露了包含免疫调节多肽的脂质纳米粒子（LNP）组合物及其用途。本公开的LNP组合物包括编码免疫调节多肽的mRNA治疗药物，例如白细胞介素2（IL-2）和/或粒细胞巨噬细胞集落刺激因子（GM-CSF）。本公开的LNP组合物可以刺激T调节细胞，例如在体内或体外增加T调节细胞的水平和/或活性。
• STEROL ANALOGS AND USES THEREOF
  申请人：ModernaTX, Inc.

  公开号：US20220402965A1

  公开（公告）日：2022-12-22

  The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.

  本发明涉及包含mRNA和脂质纳米粒子的组合物的制备、制造和治疗用途的方法和组合物，所述脂质纳米粒子包括本发明的化合物和可离子化脂质。
• COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
  申请人：ModernaTX, Inc.

  公开号：US20190314291A1

  公开（公告）日：2019-10-17

  The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
• [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DESTINÉS À L'ADMINISTRATION D'AGENTS À DES CELLULES IMMUNITAIRES
  申请人：MODERNATX INC

  公开号：WO2019152557A1

  公开（公告）日：2019-08-08

  The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
• [EN] COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR UNE ADMINISTRATION AMÉLIORÉE D'AGENTS
  申请人：MODERNA TX INC

  公开号：WO2021026358A1

  公开（公告）日：2021-02-11

  The disclosure features target cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to target cells, in particular liver cells and/or splenic cells. The LNPs comprise an effective amount of a target cell delivery potentiating lipid such that delivery of an agent by a target cell target cell delivery LNP is enhanced as compared to an LNP lacking the target cell delivery potentiating agent. Methods of using the target cell target cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, and for modulating target cell activity are also disclosed.